ADA Scientific Sessions 2025 Abstract · Jun 13, 2025

Enhanced Renal Protective Effects of Tirzepatide in T2D People

By KANEKO S, HIROBATA T

Introduction and Objective: In Japan, 1/400 diabetes people undergo hemodialysis. Chronic Kidney Disease (CKD) can lead to cardiovascular events (CV). Early detection and protection against renal failure is paramount. A report has revealed GLP-1RAg provides renal protection and decreases CV in Type 2 Diabetes (T2D) people. However, effects of GIP, another incretin hormone, on renal function are unknown. This study analyzed whether Tirzepatide (Tir), GLP-1RAg/GIPR agonist, has enhanced renal protection compared to GLP-1RAg therapy alone in real-world long duration applications. Methods: Retrospective univariate and multivariate analyses regarding HbA1c, eGFR, body weight and age were performed on three groups, A) eGFR >60, B) eGFR 59~30, and C) eGFR <30, of T2D cases receiving Tir or GLP1RAg for 12 months or more from 04/2023. Adverse events were monitored. Results: Of 367 T2D cases new to Tir (male 209, age 66.8±14.4, starting HbA1c 8.0±1.5%), 267 were analyzed (male 150, age 62±15, BMI 25.9±7.2, starting HbA1c 8.2±3.4%) and achieved HbA1c 6.7±2.4 % (P<0.01) over more than 1 years. In group B (70 cases/male 50, HbA1c 7.9 ± 1.5%, eGFR 42.2 ± 7.4), 43 improved significantly (eGFR 50 ± 8.7 was 50.1 ± 11.4 (P < 0.01)), 3 were unchanged and 24 worsened (eGFR 50 ± 8.7 was 5.1 ± 11.4 (P < 0.01)). Tir eGFR provided significant favorable changes compared to semagletide injections, GLP-1RAg alone (P<0.01). No significant difference in weight loss occured. Group A (187 cases/male 92, HbA1c 8.1±1.6%, eGFR 85.5±18.1) and C (16 cases/male 11, HbA1c 8.7±1.3%, eGFR 20.9±6.6) had no significant changes. Reasons for discontinuation were excessive weight loss, appetite loss or nausea/vomiting. Conclusion: This study suggests addition of GIP to GLP-1 signaling enhances reno-protective effects and prevents renal impairment more than GLP1RAg alone without serious side effects and may lead to comparable reductions in CVs. This could result in greater general well-being and immense medical cost savings. Observations in larger numbers are needed. Disclosure: S. Kaneko: Speaker's Bureau; Mitsubishi Tanabe Pharma Corporation, Novo Nordisk. Research Support; Novo Nordisk. Consultant; Novo Nordisk. Speaker's Bureau; AstraZeneca, Kowa Company, Ltd, Eli Lilly and Company. Research Support; Eli Lilly and Company. Speaker's Bureau; Novartis Pharmaceuticals Corporation, Sumitomo Dainippon Pharma Co., Ltd, Otsuka Pharmaceutical. T. Hirobata: Consultant; OtsukaPharmaceutical Co.,Ltd, Kowa Company, Ltd, Sanofi, Sumitomo Dainippon Pharma Co., Ltd, Taisho Pharmaceutical Holdings Co., Ltd, Novartis Pharmaceuticals Corporation, Novo Nordisk, Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim, Mochida pharmaceutical Co., Ltd. Research Support; Novo Nordisk.

doi.org/10.2337/db25-378-pInterventions

AgingResearch.News